Led by Qualcomm, Gregory Lucier Makes First Investment after Leading Life Technologies
SAN DIEGO, July 17, 2014 — Edico Genome announced today that it has raised $10 million in a Series A financing to commercialize its DRAGEN™ Bio-IT Processor, the world’s first next-generation sequencing bioinformatics application-specific integrated circuit (ASIC). The financing was led by Qualcomm Incorporated, through its venture investment group, Qualcomm Ventures, and included Axon Ventures and Greg Lucier, who made his first investment following his role as chairman and chief executive officer of Life Technologies. Concurrent with the financing, Mr. Lucier was appointed to the Edico Genome board of directors. Advisory board members include Eric Topol, M.D., professor of genomics, The Scripps Research Institute, Charles Cantor, Ph.D., chief scientific officer, Sequenom, and Nils Homer, Ph.D., genomics informatics leader, Broad Institute. The financing will be used for commercialization of DRAGEN, which is expected to broadly launch at the American Society of Human Genetics annual meeting in October.